Rapporten
Verificerede nyheder om finansiering, hovedkvarterer og ledelse fra verdens mest innovative virksomheder
343 rapporter og tæller
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Microbiotica Raises £36M Series C for Oral Microbiome Medicines
Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.
OMass Therapeutics Raises $310M Series C for Small-Molecule Therapeutics
OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance its small molecule pipeline in endocrinology and immunology.
TETRAPHARM Appoints Rolf Sass Sørensen Chief Executive Officer
TETRAPHARM appointed Rolf Sass Sørensen, formerly of Bavarian Nordic, as CEO to succeed co-founder Martin Rose and lead the Danish biopharmaceutical company’s continued development.
KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor
KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Slingshot Biosciences Appoints Dr. Nimisha Srivastava CEO
Slingshot Biosciences promoted Chief Operating Officer Dr. Nimisha Srivastava to CEO to lead commercial growth and product development.
Claris Bio Relocates Corporate Headquarters to South San Francisco
Claris Bio will relocate its corporate headquarters from Jersey City to South San Francisco in October 2026 as it advances CSB-001.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Viser 9 rapporter • Side 1 • Kategori: all
Hold dig foran markedet
Få ugentlig indsigt leveret til din indbakke. Ingen spam, kun intelligens.